The costs and benefits were combined to give a cost per exacerbation-free patient, cost per improvement in cough symptoms, cost per improvement in wheeze symptoms, and cost per symptom-free day.
The cost per exacerbation-free patient was DK 20.5 in the FP 100 microg/day group, DK 19.5 in the FP 200 microg/day group, and DK 34.8 in the placebo group.
The cost per improvement in cough symptoms was DK 27.7 in the FP 100 microg/day group, DK 24.9 in the FP 200 microg/day group, and DK 53.3 in the placebo group.
The cost per improvement in wheeze symptoms was DK 48.2 in the FP 100 microg/day group, DK 47.5 in the FP 200 microg/day group, and DK 106.7 in the placebo group.
The cost per symptom-free day was DK 6.1 in the FP 100 microg/day group, DK 7.2 in the FP 200 microg/day group, and DK 9.2 in the placebo group.